About Infensa
Infensa is a company based in Sydney (Australia) founded in 2021. Infensa has raised $15.6 million across 1 funding round from investors including Australian Unity. Infensa offers products and services including Cardiovascular Drugs. Infensa operates in a competitive market with competitors including Acticor Biotech, Basking Biosciences, 4TEEN4 Pharmaceuticals, AptaTargets and CeleCor Therapeutics, among others.
- Headquarter Sydney, Australia
- SectorsHealthcare
- Email••••••••
- Website infensabioscience.com
- Social LinkedIn Facebook
- Legal Name Infensa Bioscience Pty Ltd
- Total Equity Funding$15.6M (USD)
in 1 rounds
- Latest Funding Round$15.6M (USD), Series B
Jul 2022
- Investors
Products & Services of Infensa
Infensa offers a comprehensive portfolio of products and services, including Cardiovascular Drugs.
Medications aimed at reducing mortality from heart attacks and strokes.
Funding Insights of Infensa
Infensa has successfully raised a total of $15.6M through 1 strategic funding round. The most recent funding activity was a Series B round of $15.6 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.6M
- Total Rounds 1
- Last Round Series B — $15.6M
- First Round $15.6M
(Jul 2022)
- Investors Count 1
All 1 funding rounds of Infensa with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | $15.6M | Series B | – | – |
1 investors in total: 1 institutional.
Investors in Infensa
Infensa has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Australian Unity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Retail banking services are provided to Australian customers. | 1840 | australianunity.com.au | Melbourne, Australia |
Investor details for Infensa
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Infensa
1 people are tracked at Infensa (1 in leadership).
| Name | Role | Group |
|---|---|---|
Mark Smythe | CEO | Leadership |
Complete people profiles for Infensa
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Infensa
2 dated milestones of Infensa across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Infensa is founded.
- Funding First funding round of $15.6M.
Competitors of Infensa
Infensa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Acticor Biotech, Basking Biosciences, 4TEEN4 Pharmaceuticals, AptaTargets and CeleCor Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| acticor-biotech.com | 2013 | Paris, France | $31.36M | – | Immunotherapeutics are developed for ischemic stroke treatment using monoclonal antibodies. | |
| baskingbiosciences.com | 2019 | Columbus, United States | $89.8M | 3 | Therapeutics for ischemic stroke treatment are developed. | |
| 4teen4.de | 2013 | Hennigsdorf, Germany | $30.68M | – | Therapeutics and diagnostics for cardiovascular diseases are developed. | |
| aptatargets.com | 2014 | Madrid, Spain | $2.98M | – | Provider of therapeutic solutions for ischemic diseases | |
| celecor.com | 2017 | San Diego, United States | $46.5M | – | POC subcutaneous injectable for myocardial infarction treatment is developed. | |
| tsillc.net | 2006 | Cambridge, United States | $7.5M | 6 | Clot-dissolving therapies using mutant prounokinase are developed for thrombotic diseases. | |
| endoprotech.com | 2005 | Louisville, United States | – | – | Liposome-based therapies are developed for myocardial infarction and liver disease. | |
| f4-pharma.com | 2013 | Vienna, Austria | – | – | Drugs are manufactured to prevent reperfusion injury after myocardial infarction. | |
| decktherapeutics.com | 2019 | Albany, United States | – | – | Drugs for traumatic brain injury and stroke are developed. |
Detailed competitors of Infensa
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Infensa
The website of Infensa (infensabioscience.com) receives about 1K visits a month.
- Monthly visits1K
▲ 493.3% vs previous month
Latest news on Infensa
Complete news archive for Infensa
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Infensa
10 companies that operate in the same segment as Infensa (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | USD 57.22 M | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Infensa
Infensa was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Infensa is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Mark Smythe is the current CEO of Infensa.
Infensa is a funded company, having raised a total of $15.6M across 1 funding round to date. The company's 1st funding round was a Series B of $15.6M, raised on Jul 2022.
Infensa was founded in 2021 in Sydney, Australia, within the biotechnology sector. Peptide-based therapeutics targeting cardiovascular disorders are developed by the company. A lead compound, IB001, is provided as a selective inhibitor of human ASIC1a, by which neurons and heart muscle cells are protected from ischemic injury. Operations focus on advancing these compounds through research and development stages.
Infensa's top competitors include Acticor Biotech, 4TEEN4 Pharmaceuticals and Basking Biosciences.
Infensa offers Cardiovascular Drugs.
Infensa has 1 investor. Key investors include Australian Unity.
Infensa operates through Infensa Bioscience Pty Ltd.